Ruan J, Bond DA, Shah B, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D et al..
2026.
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.. Blood Adv. 10(4):1381-1394.
Nazzaro M, Mardis ER, Canella A, Bhinder B, Elemento O, Behbehani G, Currier M, Glaspell A, Lee DA, Cripe TP et al..
2026.
Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression.. Mol Ther Oncol. 34(1):201147.
Purkayastha S, Park J, Beyer S, Chandra A, Markowitz SM, Lerman BB, Elemento O, Krumsiek J, Lo JC, Cheung JW.
2026.
Utilization of Serum Metabolomics and Polygenic Risk Scores in a Novel Risk Stratification Tool for the Prediction of Incident Atrial Fibrillation.. Circ Arrhythm Electrophysiol. :e013858.
Assaad MAl, Hadi K, Levine MF, Guevara D, Patel M, Tranquille M, King A, Otilano J, Semaan A, Gundem G et al..
2026.
Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort.. Commun Med (Lond). 6(1):5.
Kozan ENur, de la Mora JDelgado-, Assaad MAl, Ginter P, Gundem G, Levine MF, Gorski K, Phan A, Beg S, Sigaras A et al..
2026.
Whole genome sequencing of locally advanced and metastatic breast carcinoma unravels relevant molecular signatures and novel events.. Pathol Res Pract. 282:156469.